LP
TRVI icon

LMR Partners’s Trevi Therapeutics TRVI Stock Holding History

LMR Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$547 – 1659
2025
Q2 		$547 Buy
+100
New +$622 ﹤0.01% 1341

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

LMR Partners's TRVI Position: Q1 2026 in Review

LMR Partners held its Trevi Therapeutics (TRVI) position steady in Q1 2026 at 100,000 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #947.

LMR Partners first reported a position in TRVI in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.25M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • LMR Partners held 100,000 shares of Trevi Therapeutics worth $1.19M as of Q1 2026.
  • LMR Partners left its Trevi Therapeutics share count unchanged in Q1 2026.
  • Trevi Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #947 holding.
  • LMR Partners first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • LMR Partners's Trevi Therapeutics position peaked at $1.25M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.